Your browser does not support iframes.
Carolinas Inc - Local Stocks
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Gilead Sciences, Inc.
(NQ:
GILD
)
56.30
USD
+1.34 (+2.44%)
Official Closing Price
/ Updated:
8:10 PM EDT, May 17, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
55.48
Bid (Size)
56.29 (2700)
Ask (Size)
56.30 (25800)
Prev. Close
54.96
Today's Range
54.65 - 56.43
52wk Range
39.20 - 79.37
Shares Outstanding
1,525,355,825
Dividend Yield
N/A
Top News
More News
Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20
May 17, 2013
from
Business Wire News Releases
UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
May 17, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8350777 for the full story.
Read More
from
StreetInsider.com News Articles
More News
Read More
Analyst Moves: NOC, GM, GILD
May 17, 2013
category
Stocks
from
Market News Video
AbbVie (ABBV) Has Plenty More Tricks Up Its Sleeve - Barron's
May 17, 2013
from
StreetInsider.com News Articles
Lightning Round: Starbucks, Gilead & More
May 16, 2013
category
Lightning Round
,
Starbucks Corp
,
Dominion Resources Inc
, and 10 more.
from
CNBC.com News
Gilead anuncia datos de respuesta del estudio de Fase 2 de idelalisib para leucemia linfática crónica no tratada con anterioridad
May 16, 2013
from
Business Wire Spanish
Strategy Behind Our Success, We Get in Early: GILD, MCP, GM and DF
May 16, 2013
from
Marketwired News Releases
With 'Cell Death' Drugs, Bristol-Myers May Win No Matter What
May 15, 2013
category
NYSE:JNJ
,
NYSE:MRK
,
NASDAQ:PCYC
, and 2 more.
from
Forbes Real Time
Gilead Offers Response Data from Phase 2 Study of Idelalisib
May 15, 2013
category
Benzinga
,
News
,
FDA
, and 1 more.
from
Latest Articles from Benzinga.com
Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia
May 15, 2013
from
Business Wire News Releases
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here
Your browser does not support iframes.
Your browser does not support iframes.